Zirabev (bevacizumab) 400 mg/16 mL concentrate for solution for infusion (Pfizer, USA) Zirabef (bevacizumab) 400 mg for intravenous injection ROCHE Switzerland Drug delivery from abroad within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Drug delivery from abroad under temperature control, payment upon receipt.

Indications:

• Treatment of metastatic colorectal cancer:
• in combination with fluoropyrimidine-based chemotherapy.
• Treatment of metastatic breast cancer
• first-line treatment in combination with paclitaxel;
• first-line treatment in combination with capecitabine (when treatment with other chemotherapy regimens, including taxanes or anthracyclines, is considered inappropriate). Patients who have received taxane- and anthracycline-based regimens in the adjuvant setting within the past 12 months should not receive Avastin® in combination with capecitabine.
• Treatment of advanced unresectable, metastatic, or recurrent non-small cell lung cancer, excluding predominantly squamous cell lung cancer:
• first-line treatment in combination with platinum-based chemotherapy.
• Treatment of advanced and/or metastatic renal cell carcinoma:
• first-line treatment in combination with interferon alfa-2a.
• Treatment of advanced (FIGO stages III B, III C, and IV) epithelial ovarian, fallopian tube, and primary peritoneal cancer in adults:
• as first-line therapy in combination with carboplatin and paclitaxel.
• Treatment of first relapse of platinum-sensitive epithelial ovarian, fallopian tube, and primary peritoneal cancer:
• in combination with carboplatin and gemcitabine in adult patients who have not received prior therapy with bevacizumab or other vascular endothelial growth factor inhibitors or vascular endothelial growth factor receptor-targeted agents.
• Treatment of recurrent platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer:
• in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in adult patients who have received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or vascular endothelial growth factor receptor-targeted agents. VEGF receptor antagonist.
• Treatment of persistent, recurrent, or metastatic cervical cancer.
• in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in adult patients who cannot receive platinum-based therapy.
•  
• ovastin, altuzan, oltuzan, avostin, ovostin.